These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
353 related articles for article (PubMed ID: 16167044)
41. Working together to enhance the efficiency of medical product development. Sanhai WR J Nucl Med; 2008 Jun; 49(6):43N-45N. PubMed ID: 18511823 [No Abstract] [Full Text] [Related]
42. What ails the FDA? Jenny-Avital ER N Engl J Med; 2005 Jun; 352(24):2554-5. PubMed ID: 15962407 [No Abstract] [Full Text] [Related]
43. Original research: Intravenous ribavirin--review of the FDA's Emergency Investigational New Drug Database (1997-2008) and literature review. Riner A; Chan-Tack KM; Murray JS Postgrad Med; 2009 May; 121(3):139-46. PubMed ID: 19491552 [TBL] [Abstract][Full Text] [Related]
45. Uncertainty surrounds cancer vaccine review at FDA. Fox JL Nat Biotechnol; 2007 Aug; 25(8):827-8. PubMed ID: 17687346 [No Abstract] [Full Text] [Related]
46. Phase 0 clinical trials in oncology: a paradigm shift for early drug development? Takimoto CH Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251 [TBL] [Abstract][Full Text] [Related]
47. Effort to privatize drug reviews grows. Scott L Mod Healthc; 1995 Jun; 25(26):54. PubMed ID: 10143746 [No Abstract] [Full Text] [Related]
49. FDA given new powers over data reporting to national clinical trials registry. Roehr B BMJ; 2012 Oct; 345():e6629. PubMed ID: 23033375 [No Abstract] [Full Text] [Related]
51. The drive to reform the FDA gains momentum. Gatty B Hosp Formul; 1995 Mar; 30(3):178, 177. PubMed ID: 10141250 [No Abstract] [Full Text] [Related]
52. Remarks of the Lead Deputy Commissioner of the Food and Drug Administration. Friedman MA Food Drug Law J; 1998; 53(1):19-23. PubMed ID: 11795333 [No Abstract] [Full Text] [Related]
53. The prevention and treatment of missing data in clinical trials: an FDA perspective on the importance of dealing with it. O'Neill RT; Temple R Clin Pharmacol Ther; 2012 Mar; 91(3):550-4. PubMed ID: 22318615 [TBL] [Abstract][Full Text] [Related]
54. Can single-patient investigational new drug studies hurry slow trains to the fast track? Chenoweth D Drug Discov Today; 2006 Mar; 11(5-6):185-6. PubMed ID: 16580594 [TBL] [Abstract][Full Text] [Related]
55. Getting SMART (submission management and review tracking) drug review in the computer age. Flieger K FDA Consum; 1995 Oct; 29(8):6-9. PubMed ID: 10151839 [TBL] [Abstract][Full Text] [Related]
56. Oncology's first Phase 0 trial. Rowan K J Natl Cancer Inst; 2009 Jul; 101(14):978-9. PubMed ID: 19584322 [No Abstract] [Full Text] [Related]
58. FDA's role in administering the Hatch-Waxman Act. Malkin BJ Food Drug Law J; 1999; 54(2):211-4. PubMed ID: 11758575 [No Abstract] [Full Text] [Related]
59. Communicating with the FDA: the "third rail" of a new model for drug development. Stanski DR; Orloff JJ J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890 [No Abstract] [Full Text] [Related]
60. Regulatory research. A centennial letdown for FDA's biologics group. Agnew B Science; 2002 Nov; 298(5599):1704-5. PubMed ID: 12459566 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]